Abstract
Currently approved options for the treatment of onychomycosis include systemic therapy (the antifungal agents fluconazole, itraconazole, and terbinafine), topical agents (ciclopirox, which has been available since 1996, efinaconazole, currently pending approval), and laser systems. Phase III studies on another topical, tavaborole, have been completed and this medication also shows promise. Mechanical modalities are sometimes used but are seldom necessary. Recurrence of infection is common; the risk for recurrence may be reduced by adherence to preventive measures, especially avoiding (if possible) or promptly treating tinea pedis infections.
Original language | English (US) |
---|---|
Pages (from-to) | S9-S12 |
Journal | Seminars in cutaneous medicine and surgery |
Volume | 32 |
DOIs | |
State | Published - Jun 1 2013 |
Keywords
- Ciclopirox
- Efinaconazole
- Fluconazole
- Fungal infections
- Itraconazole
- Nail infections
- Onychomycosis
- Tavaborole
- Terbinafines
ASJC Scopus subject areas
- Surgery
- Dermatology